Last quarter (Q3 2023), Pieris Pharmaceuticals's total revenue was $19.52M, an increase of 263.50% from the same quarter last year. In Q3, Pieris Pharmaceuticals's net income was $-10.75M. See Pieris Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 49.05M	$ 25.90M	$ 3.69M	$ 29.32M	$ 46.28M	$ 29.10M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 48.97M	$ 25.90M	$ 3.69M	-	-	-
Operating Expense	$ 14.51M	$ 69.38M	$ 83.25M	$ 63.24M	$ 73.44M	$ 59.93M
Operating Income	$ -8.05M	$ -43.47M	$ -79.56M	$ -33.92M	$ -27.16M	$ -30.83M
Net Non Operating Interest Income Expense	$ 279.00K	$ 721.00K	$ 4.00K	$ 511.00K	$ 1.71M	$ 1.96M
Other Income Expense	$ -19.84M	$ -9.91M	$ -33.82M	$ -3.66M	$ -26.00K	$ 1.80M
Pretax Income	$ 8.12M	$ -33.28M	$ -45.74M	$ -37.07M	$ -25.47M	$ -27.07M
Tax Provision	-	-	-	$ 164.00K	$ 0.00	$ -312.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ 4.80M	$ -33.28M	$ -45.74M	$ -37.23M	$ -28.30M	$ -26.75M
Basic EPS	$ -0.35	$ -0.45	$ -0.71	$ -0.68	$ -0.56	$ -0.50
Diluted EPS	$ -0.03	$ -0.45	$ -0.71	$ -0.68	$ -0.56	$ -0.50
Basic Average Shares	$ 335.18M	$ 74.17M	$ 64.55M	$ 54.48M	$ 50.63M	$ 53.08M
Diluted Average Shares	$ 261.20M	$ 74.17M	$ 64.55M	$ 54.48M	$ 50.63M	$ 53.08M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 14.51M	$ 69.38M	$ 83.25M	$ 63.24M	$ 73.44M	$ 59.93M
Net Income From Continuing And Discontinued Operation	$ -28.06M	$ -33.28M	$ -45.74M	$ -37.23M	$ -25.47M	$ -26.75M
Normalized Income	$ 9.54M	$ -26.29M	-	$ -37.23M	$ -25.47M	$ -26.75M
Interest Expense	-	-	-	-	-	-
EBIT	$ 9.24M	$ -33.28M	$ -45.74M	$ -33.92M	$ -27.16M	$ -30.83M
EBITDA	$ 11.91M	$ -30.51M	$ -43.28M	$ -31.79M	$ -26.12M	$ -30.26M

Currency in USD

Pieris Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing